| Literature DB >> 9724791 |
L Yang1, S C Berk, S P Rohrer, R T Mosley, L Guo, D J Underwood, B H Arison, E T Birzin, E C Hayes, S W Mitra, R M Parmar, K Cheng, T J Wu, B S Butler, F Foor, A Pasternak, Y Pan, M Silva, R M Freidinger, R G Smith, K Chapman, J M Schaeffer, A A Patchett.
Abstract
A series of nonpeptide somatostatin agonists which bind selectively and with high affinity to somatostatin receptor subtype 2 (sst2) have been synthesized. One of these compounds, L-054,522, binds to human sst2 with an apparent dissociation constant of 0.01 nM and at least 3,000-fold selectivity when evaluated against the other somatostatin receptors. L-054,522 is a full agonist based on its inhibition of forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary-K1 cells stably expressing sst2. L-054,522 has a potent inhibitory effect on growth hormone release from rat primary pituitary cells and glucagon release from isolated mouse pancreatic islets. Intravenous infusion of L-054,522 to rats at 50 microgram/kg per hr causes a rapid and sustained reduction in growth hormone to basal levels. The high potency and selectivity of L-054, 522 for sst2 will make it a useful tool to further characterize the physiological functions of this receptor subtype.Entities:
Mesh:
Substances:
Year: 1998 PMID: 9724791 PMCID: PMC27982 DOI: 10.1073/pnas.95.18.10836
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205